Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients

Oncotarget

Volumn 5, Issue 10, 2014, Pages 3076-3087

  Wikman, Harriet ^a   Westphal, Laura ^a   Schmid, Felicitas ^a,b   Pollari, Sirkku ^c   Kropidlowski, Jolanthe ^a   Sielaff Frimpong, Bettina ^a   Glatzel, Markus ^a   Matschke, Jakob ^a   Westphal, Manfred ^a   Iljin, Kristiina ^c   Huhtala, Heini ^d   Terracciano, Luigi ^e   Kallioniemi, Anne ^d   Sauter, Guido ^a   Müller, Volkmar ^a   Witzel, Isabell ^a   Lamszus, Katrin ^a   Kemming, Dirk ^f   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY OF TURKU   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f European Laboratory Association   (Germany)

Author keywords

Brain metastases; breast cancer; CADM1; Methylation

Indexed keywords

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CADM1 GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CXCL14 GENE; DISEASE MARKER; GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; METHYLATION; PROTEIN EXPRESSION; PROTEIN METHYLATION; RECEPTOR DOWN REGULATION; RECK GENE; SPARC GENE; TNFAIP3 GENE; TUMOR VOLUME; BIOSYNTHESIS; BRAIN TUMOR; BREAST TUMOR; FEMALE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; SECONDARY; TUMOR CELL LINE;

CADM1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; TRANSCRIPTOME; TUMOR MARKER;

BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84902119915     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1832     Document Type: Article

References (37)

1. Lin NU, Bellon JR and Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004; 22(17):3608-3617.
2. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P and Goncalves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012; 32(11):4655-4662.
3. Arslan UY, Oksuzoglu B, Aksoy S, Harputluoglu H, Turker I, Ozisik Y, Dizdar O, Altundag K, Alkis N and Zengin N. Breast cancer subtypes and outcomes of central nervous system metastases. Breast. 2011; 20(6):562-567.
4. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M and Perou CM. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat. 2011; 132(2):523-535.
5. Shoushtari AN, Szmulewitz RZ and Rinker-Schaeffer CW. Metastasis-suppressor genes in clinical practice: lost in translation? Nat Rev Clin Oncol. 2011; 8(6):333-342.
6. Horak CE, Lee JH, Marshall JC, Shreeve SM and Steeg PS. The role of metastasis suppressor genes in metastatic dormancy. APMIS. 2008; 116(7-8):586-601.
7. Hurst DR and Welch DR. Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol. 2011; 286:107-180.
8. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA and Massague J. Genes that mediate breast cancer metastasis to the brain. Nature. 2009; 459(7249):1005-1009.
9. Overmeer RM, Henken FE, Snijders PJ, Claassen-Kramer D, Berkhof J, Helmerhorst TJ, Heideman DA, Wilting SM, Murakami Y, Ito A, Meijer CJ and Steenbergen RD. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol. 2008; 215(4):388-397.
10. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, Sekiya T, Reeves RH and Murakami Y. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet. 2001; 27(4):427-430.
11. Clark JC, Thomas DM, Choong PF and Dass CR. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev. 2007; 26(3-4):675-683.
12. Arnold SA and Brekken RA. SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal. 2009; 3(3-4):255-273.
13. Gu XL, Ou ZL, Lin FJ, Yang XL, Luo JM, Shen ZZ and Shao ZM. Expression of CXCL14 and its anticancer role in breast cancer. Breast Cancer Res Treat. 2012; 135(3):725-735.
14. Ungerback J, Belenki D, Jawad Ul-Hassan A, Fredrikson M, Fransen K, Elander N, Verma D and Soderkvist P. Genetic variation and alterations of genes involved in NFkappaB/TNFAIP3-and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis. 2012; 33(11):2126-2134.
15. Nakahata S and Morishita K. CADM1/TSLC1 is a novel cell surface marker for adult T-cell leukemia/lymphoma. J Clin Exp Hematop. 2012; 52(1):17-22.
16. Liang QL, Chen GQ, Li ZY and Wang BR. Function and histopathology of a cell adhesion molecule TSLC1 in cancer. Cancer Invest. 2011; 29(2):107-112.
17. Faraji F, Pang Y, Walker RC, Nieves Borges R, Yang L and Hunter KW. Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. PLoS Genet. 2012; 8(9):e1002926.
18. Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F and Murakami Y. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer. 2011; 19(3):242-252.
19. Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, Pirker R, Zielinski CC and Zochbauer-Muller S. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat. 2007; 103(3):283-291.
20. Silveira Correa TC, Massaro RR, Brohem CA, Taboga SR, Lamers ML, Santos MF and Maria-Engler SS. RECK-mediated inhibition of glioma migration and invasion. J Cell Biochem. 2010; 110(1):52-61.
21. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, Maher ER and Latif F. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011; 71(8):2988-2999.
22. Hsu MC, Chang HC and Hung WC. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem. 2006; 281(8):4718-4725.
23. Brekken RA and Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001; 19(8):816-827.
24. Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger RB, Netto MM and Soares FA. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat. 2011; 126(1):1-14.
25. Hymowitz SG and Wertz IE. A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer. 2010; 10(5):332-341.
26. Song EY, Shurin MR, Tourkova IL, Gutkin DW and Shurin GV. Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells. Cancer Res. 2010; 70(11):4394-4401.
27. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y and Seto M. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009; 114(12):2467-2475.
28. Pollari S, Kakonen SM, Edgren H, Wolf M, Kohonen P, Sara H, Guise T, Nees M and Kallioniemi O. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat. 2011; 125(2):421-430.
29. Yoneda T, Williams PJ, Hiraga T, Niewolna M and Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2001; 16(8):1486-1495.
30. Wikman H, Sielaff-Frimpong B, Kropidlowski J, Witzel I, Milde-Langosch K, Sauter G, Westphal M, Lamszus K and Pantel K. Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases. PLoS One. 2012; 7(10):e47537.
31. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP and Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001; 159(6):2249-2256.
32. Alarmo EL, Huhtala H, Korhonen T, Pylkkanen L, Holli K, Kuukasjarvi T, Parkkila S and Kallioniemi A. Bone morphogenetic protein 4 expression in multiple normal and tumor tissues reveals its importance beyond development. Mod Pathol. 2013; 26(1):10-21.
33. Hein S, Muller V, Kohler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Ihnen M, Beck K, Issa R, Janicke F, Pantel K and Milde-Langosch K. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue. Breast Cancer Res Treat. 2011; 129(2):347-360.
34. Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmen J, Yekebas EF, Izbicki JR, Brakenhoff RH, Streichert T, Riethdorf S, Glatzel M, Ylstra B, Pantel K and Wikman H. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res. 2009; 15(5):1566-1574.
35. Wischnewski F, Pantel K and Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1,-A2,-A3, and-A12 in human cancer cells. Mol Cancer Res. 2006; 4(5):339-349.
36. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y and Sukumar S. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006; 66(13):6512-6520.
37. Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, Sauter G, Kemming D, Glatzel M, Muller V, Westphal M and Pantel K. Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res. 2012; 14(2):R49.